| Phase 3 | Schizophrenia | - |
| Phase 3 | Rheumatoid Arthritis | - |
Hyalein Mini Ophthalmic solution | Phase 3 | Dry Eye Syndromes | - |
| Phase 3 | Cardiac Edema | - |
| Phase 3 | Migraine | - |
| Phase 3 | Moderate Acute Asthma | - |
OPC-12759 Ophthalmic suspension | Phase 3 | Dry Eye Syndromes | - |
| Phase 3 | Schizophrenia | - |
| Phase 3 | Crohn's Disease | - |
| Phase 3 | Depressive Disorder | - |
OPC-34712FUM/ Brexpiprazole fumarate | Phase 3 | Acute Schizophrenia | - |
| Phase 3 | Ulcerative Colitis | - |
| Phase 3 | Agitation in Participants With Dementia of the Alzheimer's Type | - |
| Phase 3 | Pulmonary Tuberculosis | - |
| Phase 3 | Attention Deficit Disorder | - |
| Phase 3 | Depressive Disorder | - |
Aripiprazole Oral Solution | Phase 3 | Autistic Disorder | - |
180mg of ETC-1002(bempedoic acid) | Phase 3 | Hyper-low-density Lipoprotein (LDL) Cholesterolemia | - |
| Phase 3 | Myelodysplastic Syndromes | - |
Cilostazol 200mg/day Oral | Phase 3 | Cerebral Infarction | - |
| Phase 3 | Post Traumatic Stress Disorder | - |
| Phase 3 | Depressive Disorder | - |
OPC-34712 [Brexpiprazole] High Dose | Phase 3 | Acute Schizophrenia | - |
Aripiprazole (BMS-337039) | Phase 3 | Dementia, Alzheimer Type | - |
| Phase 3 | Depressive Disorder | - |
| Phase 3 | Ulcerative Colitis | - |
| Phase 3 | Migraine | - |
| Phase 3 | Acute Gastritis | - |
Abilify 2, 5, 10, 15mg (Tablet) | Phase 3 | Depression, Bipolar | - |
| Phase 3 | Agitation Associated With | - |
Rebamipide and Omeprazole | Phase 3 | Gastric Ulcer | - |
OPC-1085EL ophthalmic solution | Phase 3 | Glaucoma | - |
| Phase 3 | Cerebral Infarction | - |
Aripiprazole depot 300 or 400 mg | Phase 3 | Schizophrenia | - |
| Phase 3 | Phenylketonuria | - |
| Phase 3 | Attention Deficit/Hyperactivity Disorder | - |
| Phase 3 | Hyperlipidemia | - |
EB-1020 (Centanafadine) 328.8 mg | Phase 3 | Attention Deficit Hyperactivity Disorder (ADHD) | - |
Centanafadine Hydrochloride | Phase 3 | Attention-Deficit/Hyperactivity Disorder | - |
| Phase 3 | Syndrome of Inappropriate Antidiuretic Hormone Secretion | - |
| Phase 3 | Atopic Dermatitis | - |
| Phase 3 | Atopic Dermatitis (AD) | - |
| Phase 3 | Schizophrenia | - |
Aripiprazole Low (2 mg/day) | Phase 3 | Schizophrenia | - |
Intramuscular (IM) Depot Aripiprazole | Phase 3 | Bipolar I Disorder | - |
| Phase 3 | Agitation Associated With | - |
| Phase 3 | Cardiac Edema | - |
Tolvaptan Matching-placebo | Phase 3 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | - |
| Phase 3 | Immunoglobulin A Nephropathy | - |
| Phase 3 | Schizophrenia | - |
| Phase 3 | Keratoconjunctivitis Sicca | - |
| Phase 3 | Open Angle Glaucoma or Ocular Hypertension | - |
Aripiprazole (Abilify®) IM Depot Injection | Phase 3 | Schizophrenia | - |
Olanzapine or Quetiapine or Risperidone | Phase 3 | Schizophrenia | - |
| Phase 3 | Rheumatoid Arthritis | - |
Aripiprazole (Fixed dose) | Phase 3 | Major Depressive Disorder | - |
| Phase 3 | Atopic Dermatitis | - |
| Phase 3 | Schizophrenia | - |
Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses. | Phase 3 | Migraine | - |
| Phase 3 | Cirrhosis | - |
| Phase 3 | Schizophrenia | - |
| Phase 3 | Rheumatoid Arthritis | - |
Brexpiprazole (OPC-34712) | Phase 3 | Schizophrenia | - |
| Phase 3 | Schizophrenia | - |
| Phase 3 | Major Depressive Disorder | - |
| Phase 3 | Major Depressive Disorder | - |
| Phase 3 | Autosomal Recessive Polycystic Kidney Disease (ARPKD) | - |
| Phase 3 | Schizophrenia | - |
| Phase 3 | Vasospastic Angina | - |
EB-1020 (Centanafadine) 164.4 mg | Phase 3 | Attention Deficit Hyperactivity Disorder (ADHD) | - |
| Phase 3 | Agitation in Patients With Dementia of the Alzheimer's Type | - |
| Phase 3 | Major Depressive Disorder | - |
| Phase 2 | Acute Myeloid Leukemia | - |
| Phase 2 | Phenylketonuria (PKU) | - |
| Phase 2 | Schizophrenia | - |
| Phase 2 | Dry Eye Syndromes | - |
| Phase 2 | Atopic Dermatitis | - |
Delamanid + Bedaquiline + OPC-167832 10 mg | Phase 2 | Pulmonary TB | - |
Sodium hyaluronate ophthalmic solution | Phase 2 | Keratoconjunctival Epithelial Disorder | - |
| Phase 2 | Major Depressive Disorder | - |
| Phase 2 | Cirrhosis | - |
| Phase 2 | Dyspeptic Subjects | - |
| Phase 2 | Myelodysplastic Syndromes | - |
OPC-64005 20 mg , Once-daily | Phase 2 | Major Depressive Disorder | - |
| Phase 2 | Gastric Acid-related Diseases | - |
| Phase 2 | Congestive Heart Failure | - |
| Phase 2 | Atopic Dermatitis | - |
| Phase 2 | Diabetic Nephropathy | - |
| Phase 2 | Hepatocellular Carcinoma | - |
Aripiprazole tablet, 5-30mg/day, oral, 6 weeks | Phase 2 | Schizophrenia | - |
| Phase 2 | Chronic Obstructive Pulmonary Disease | - |
| Phase 2 | Adult Attention Deficit Hyperactivity Disorder | - |
| Phase 2 | Pulmonary TB | - |
| Phase 2 | Head and Neck Cancer | - |
| Phase 2 | Idiopathic Restless Legs Syndrome | - |
| Phase 2 | Tuberculosis, Multidrug-Resistant | - |
| Phase 2 | Peripheral Artery Disease | - |
| Phase 2 | Pain Due to Osteoporosis | - |
| Phase 2 | Parkinson Disease Psychosis | - |
1% OPC-12759 ophthalmic suspension | Phase 2 | Dry Eye Syndromes | - |
| Phase 2 | Major Depressive Disorder | - |
| Phase 2 | Attention Deficit Disorder With Hyperactivity | - |
| Phase 2 | Multiple Myeloma | - |
Optimized Background Regimen (OBR) | Phase 2 | Tuberculosis, Pulmonary | - |
